SH3YL1 Antibodies, Compositions, Diabetic Nephropathy Treatment
Summary
USPTO published patent application US20260109755A1 for SH3YL1 monoclonal antibodies and compositions for treating diabetic nephropathy, non-alcoholic steatohepatitis, acute kidney injury, and inflammatory bowel disease. Filed December 16, 2025 under Application No. 19421272 by five named inventors including Yun Soo Bae, Eunjung An, and Jung-Yeon Yoo. The application claims priority for genetic sequences, compositions, and therapeutic methods using SH3YL1 antibodies, but does not yet grant enforceable patent rights.
“The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
USPTO published patent application US20260109755A1 disclosing SH3YL1 monoclonal antibodies, isolated nucleic acid molecules encoding them, vectors, host cells, and compositions, along with methods of treating diabetic nephropathy, non-alcoholic steatohepatitis, acute kidney injury, and inflammatory bowel disease using the antibodies. The A1 publication makes the application publicly available for examination and potential opposition.
Biopharmaceutical companies developing kidney disease, liver disease, or inflammatory bowel disease therapeutics should review the application claims for potential freedom-to-operate concerns or licensing opportunities. The December 16, 2025 filing date establishes priority, and competitors filing similar applications after that date may face patentability challenges for overlapping subject matter.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof
Application US20260109755A1 Kind: A1 Apr 23, 2026
Inventors
Yun Soo BAE, Eunjung AN, Jung-Yeon YOO, Hyunbo SHIM, Hye Eun LEE
Abstract
The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
CPC Classifications
C07K 16/18 A61P 1/16 A61P 13/12 G01N 33/6854 A61K 2039/505 C07K 2317/52 C07K 2317/55 C07K 2317/565 C07K 2317/622 C07K 2317/624
Filing Date
2025-12-16
Application No.
19421272
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.